Get the Stockscreener App
7.69
2.54%
-0.17
Tonix Pharmaceuticals Holding Corp stock is traded at $7.69, with a volume of 107.47K.
It is down -2.54% in the last 24 hours and down -60.70% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$7.86
Open:
$7.79
24h Volume:
107.47K
Relative Volume:
0.08
Market Cap:
$44.24M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-0.6829
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
-12.66%
1M Performance:
-60.70%
6M Performance:
-54.38%
1Y Performance:
-99.35%
1-Day Range:
$7.65
$7.9786
1-Week Range:
$7.54
$9.139
52-Week Range:
$7.54
$1,221.76
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
7.65 | 44.24M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.63 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.49 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.75 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.35 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.69 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharm stock plunges to 52-week low of $7.84 By Investing.com - Investing.com Australia
Tonix Pharm stock plunges to 52-week low of $7.84 - Investing.com
Tonix reports positive results in TNX-1500 phase 1 trial - MSN
TNXP: PDUFA Date for TNX-102 SL in Fibromyalgia of August 15, 2025 - Smartkarma
TNXP: PDUFA Date for TNX-102 SL in Fibromyalgia of August 15, 2025… - Yahoo Finance
(TNXP) Investment Analysis - Stock Traders Daily
(TNXP) On The My Stocks Page - Stock Traders Daily
Tonix Pharmaceuticals appoints new CTO amid drug development - MSN
Tonix Pharmaceuticals reports positive phase 1 results for TNX-1500, advancing to Phase 2 - Proactive Investors USA
Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights - ADVFN
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap DownHere's Why - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap UpWhat's Next? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 13.2%Should You Buy? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 12.6%Time to Sell? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7%Should You Sell? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.7%What's Next? - MarketBeat
Tonix Pharma says it had about $98.8M in cash and cash equivalents as of Dec 31, 2024 - MSN
Tonix Pharmaceuticals Rises After Preliminary 2024 Results -February 07, 2025 at 03:39 pm EST - Marketscreener.com
Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash - GlobeNewswire
Tonix stock gains on business update, preliminary earnings report - Seeking Alpha
What's Going On With Tonix Pharmaceuticals Shares Friday? - Benzinga
Tonix Pharmaceuticals reports positive topline trial outcomes of TNX-1500 - Clinical Trials Arena
TNXP Financial Results: Strong Sales Growth & Strategic Cash Position Ahead of Critical FDA Date - StockTitan
Tonix Pharma Announces Promising Phase 1 Trial Results - TipRanks
Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases - GlobeNewswire
Breakthrough in Transplant Medicine: Novel Anti-CD40L Antibody Achieves Key Clinical Milestones - StockTitan
Tonix Pharmaceuticals announces reverse stock split - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated by Analysts at StockNews.com - MarketBeat
TNXPTonix Pharmaceuticals Holding Corp. Latest Stock News & Market Updates - StockTitan
Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference on February 10, 2025 - Nasdaq
Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference - GlobeNewswire
Tonix's FDA Fast-Tracked Fibromyalgia Treatment Takes Center Stage at Major Investor Conference - StockTitan
Tonix Pharmaceuticals appoints new CTO amid drug development By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals promotes Fogarty to CTO - MSN
Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer - citybiz
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 7.7%Should You Sell? - MarketBeat
Tonix Pharma Promotes Fogarty to Chief Technology Officer - TipRanks
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Craters on Stock Split before FDA Call - TipRanks
Tonix's Leadership Shakeup: New CTO to Spearhead $34M Defense Contract & Critical FDA Review - StockTitan
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 11.5% HigherWhat's Next? - MarketBeat
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 6.7%Should You Buy? - MarketBeat
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.91%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):